1 **RESEARCH ARTICLE**

- 2 Global seasonal activities of respiratory syncytial virus before the COVID-19 pandemic:
- 3 a systematic review
- 4 Songwei Shan^{1,2}, Weixin Zhang¹, Huizhi Gao¹, Pei-Yu Huang¹, Zhanwei Du^{1,2}, Yuan Bai^{1,2},
- 5 Yiu-Chung Lau^{1,2}, Dongxuan Chen^{1,2}, Eric HY Lau^{1,2}, Joshua Nealon¹, Peng Wu^{1,2}
- 6
- ¹World Health Organization Collaborating Centre for Infectious Disease Epidemiology and
- 8 Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong
- 9 Kong, Hong Kong SAR, China.
- ¹⁰ ²Laboratory of Data Discovery for Health, Hong Kong Science and Technology Park, Hong
- 11 Kong SAR, China.
- 12
- 13
- 14 Corresponding author: Peng Wu, School of Public Health, The University of Hong Kong,
- 15 email: pengwu@hku.hk, Tel: 3917 6746
- 16
- 17 Running head: Global RSV seasonality
- 18
- 19 Word count (Abstract): 248
- 20 Word count (main text): 3,356
- 21 Keywords: activity, respiratory syncytial virus, seasonality, global

22 ABSTRACT

Background: Varied seasonal patterns of respiratory syncytial virus (RSV) have been reported worldwide. We aimed to review the patterns of RSV activity globally before the COVID-19 pandemic and to explore factors potentially associated with RSV seasonality.
Methods: We conducted a systematic review on articles identified in PubMed reporting RSV seasonality based on data collected before 1 January 2020. Information on the timing of the start, peak, and end of an RSV season, study location, study period, and details in study methods were extracted. RSV seasonal patterns were examined by geographic location.

29 methods were extracted. RSV seasonal patterns were examined by geographic location, 30 calendar month, analytic method and meteorological factors including temperature and 31 absolute humidity. Correlation and regression analyses were conducted to explore the 32 relationship between RSV seasonality and study methods and characteristics of study 33 locations.

Results: RSV seasons were reported in 209 articles published in 1973-2023 for 317 locations in 77 countries. Variations were identified in types of data, data collection and analytical methods across the studies. Regular RSV seasons were similarly reported in countries in temperate regions, with highly variable seasons identified in subtropical and tropical countries. Durations of RSV seasons were relatively longer in subtropical and tropical regions than from temperate regions. Longer durations of RSV seasons were associated with a higher daily average mean temperature and daily average mean absolute humidity.

41 **Conclusions:** The global seasonal patterns of RSV provided important information for 42 optimizing interventions against RSV infection. Heterogeneity in study methods highlighted 43 the importance of developing and applying standardized approaches in RSV surveillance and 44 data reporting.

45 **INTRODUCTION**

46 Respiratory syncytial virus (RSV) is a leading cause of hospitalization for acute lower 47 respiratory tract infection (LRTI) in young children less than 5 years old ¹⁻³, as well as an increasingly recognized important pathogen in older adults (aged ≥ 65)^{4,5}. Globally, RSV 48 49 was estimated to cause nearly 25 million LRTI episodes and more than 70,000 deaths every year ⁶. In addition to Palivizumab, a monoclonal antibody recommended for high-risk infants 50 51 ^{7,8} providing a short-term protection against RSV-associated severe infections ^{9,10}, a new monoclonal antibody nirsevimab with a prolonged protection ^{11,12} has been approved by the 52 EU and the UK¹³. Recently the first RSV vaccine (Arexvy, RSVPreF3 from GSK) approved 53 54 for the use in older adults and several other vaccine candidates in their final stage of testing demonstrated promising efficacy in preventing RSV-associated LRTI and severe infections 55 14,15 56

57

58 Activities of RSV varied temporally and geographically. In temperate regions, the highest viral activities have been observed during winter months ^{16,17} with similar intensities across 59 60 different years. Two-year cycles of RSV activity have been reported for some countries in 61 Northern Europe, with a major epidemic wave in winter followed by a minor one in spring next year ¹⁸. In subtropical and tropical regions, seasonal patterns of RSV were more diverse 62 and less clear than those reported for temperate countries ¹⁹. Knowledge about the seasonality 63 64 of RSV, can guide the formulation of prevention strategies and the planning of public health 65 resources. In particular, accurate estimates of the RSV season start and its duration can help 66 to determine the optimal timing of initial doses and optimal dosing interval for prophylactic 67 monoclonal antibodies and vaccination schedules.

We conducted a systematic review on RSV seasonality to characterize the global patterns of RSV activity by summarizing the reported start, peak and end of RSV seasons worldwide and describe approaches applied in analyzing the seasonality. We aimed to provide a better understanding of the seasonal patterns of RSV circulation to inform policy and decisions in prevention, diagnosis, and treatment of RSV infections.

74

75 **METHODS**

76 Literature search strategy and selection criteria

This systematic review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines ²⁰. We focused on studies in which seasonal patterns of RSV were characterized by providing the time of the start, peak and/or end of a season based on laboratory-confirmed RSV infection data. We searched published articles from PubMed on January 17, 2023 using the combination of following search items (*1 and 2*) in "Title/Abstract" (Figure 1):

83 1. "RSV" or "Respiratory Syncytial Virus"

- 84 2. "seasonality" or "season*"
- 85

Two authors (S.S. and W.Z.) performed the literature search (#1 and #2) and screened retrieved articles independently. Full-text screening was conducted after title/abstract screening. Two authors (S.S. and W.Z.) independently identified articles for inclusion. Any disagreement in article selection and data retrieval was resolved by a third author (P.W.).

90

Eligible articles were studies reporting the seasonality of RSV based on monthly or weekly laboratory-confirmed RSV infections collected for a specified place, i.e., a city, a province or a country, for three years or longer. We excluded articles if: 1) the full text was not available

or not in English, 2) the analysis was based on less than three years' data, 3) the average
number of reported RSV infections per year in a study was less than 50, 4) the time of the
start, peak and/or end of RSV seasons was not specified in a calendar month or week. If an
investigation on RSV seasonality covered the time period beyond 2019, the study period
before the COVID-19 pandemic ≥ 3 years would be included in our analysis, and the RSV
data collected during the pandemic would be excluded. Articles without original data analysis

- 100 on RSV activities, such as reviews, commentaries, letters, were excluded, but we reviewed
- 101 the references of these articles for additional studies to include for screening.
- 102

103 Data extraction and analysis

104 Two authors (S.S. and W.Z.) independently extracted data into a standardized data extraction 105 form. Data fields included the timing (start, peak, and end) of an RSV season, study location 106 (city, region or country), study period, information on study characteristics (such as the 107 source of cases, case definitions, laboratory testing methods and analytic methods applied to 108 determine RSV seasons). We classified the sources of study cases into outpatient, inpatient, 109 outpatient and inpatient, case definitions into influenza-like-illness (ILI) or acute respiratory 110 infection (ARI), severe acute respiratory infection (SARI) and acute LRTI and grouped 111 laboratory testing methods for RSV confirmation into virus detection, antibody detection, 112 antigen detection, and nucleic acid detection.

113

One publication might contain several different investigations on seasonal patterns of RSV, either based on different data sources, or based on the same dataset but with different analytic methods. If more than one estimate on timing of RSV season was reported in a single publication, using different data sources or methods, all were extracted and included in our analyses. It was common that one investigation on RSV seasonality was conducted based on

more than one type of case source, case definition and/or testing method, and all the methodological details were extracted and documented for analyses. Analytic methods used by different studies to determine the RSV seasons were classified as qualitative methods and quantitative methods based on whether the analysis on RSV seasonality was carried out using a statistical or mathematical approach, and the quantitative methods were further divided into three groups, threshold-based, coverage-based and model-based (*Supplementary Materials*).

125

126 In addition to the study-specific information, we also documented the latitude, daily average 127 mean temperature and daily average mean relative humidity for all study locations reported in each investigation using Google Geocoding API²¹ and R package GSOR²²(Supplementary 128 129 materials). The extracted daily average mean temperature and relative humidity data were 130 used to derive the daily average mean absolute humidity for each location. We also extracted 131 the geoclimatic information of each study site, and classified the investigations of RSV 132 seasonality into three groups based on the latitude of the study sites, temperate zone (latitude > 133 35° or latitude < -35°), subtropical zone (23.5° < latitude \leq 35° or -35° \leq latitude < -23.5°) 134 and tropical zone (-23.5° \leq latitude \leq 23.5°).

135

We described the reported RSV seasons as a function of geographical location, meteorological factors and characteristics of study design, and explored potential associations using Pearson correlation analyses and Kendall's rank correlation between the duration of the season and the latitude, daily average mean temperature and daily average mean absolute humidity of study sites as well as the analytic method and climate zone. Finally, linear regression models were applied to explore the independent associations between the duration of RSV seasons and the abovementioned factors as covariates. The statistical analyses were

143 conducted using R software Version 4.0.3 (R Foundation for Statistical Computing, Vienna,144 Austria).

145

146 **RESULTS**

147 We identified 2,510 citations from the PubMed through the keyword search and additional 19

148 citations from other sources. In total, 209 publications were included after screening based on

- 149 the inclusion and exclusion criteria (Figure 1) and 552 investigations of RSV seasonality
- 150 were identified and included in analyses.
- 151

152 The identified studies were published between 1973 and 2023, with the majority (147/209,

153 70%) from 2010 onwards (Supplementary Figure 1). RSV seasonality was reported for 317

154 distinct study sites in 77 countries from Asia, Europe, North America, South America, 155 Oceania and Africa (Figure 2). Most investigations (342/552, 62%) were conducted with a 156 study period of 3-6 years (Supplementary Figure 1), with the longest one from Malaysia 157 using surveillance data over 27 years²³. Among the identified publications, more than half 158 (124/209, 59%) were from temperate regions (latitude > 35° or latitude < -35°), followed by 159 31% (65/209) and 22% (47/209) in subtropical (23.5° < latitude $\leq 35^\circ$ or $-35^\circ \leq$ latitude < -160 (-23.5°) and tropical $(-23.5^{\circ} \le \text{latitude} \le 23.5^{\circ})$ regions, respectively (Table 1, Supplementary 161 Table 1).

162

The information on the case source, case definition, and laboratory testing methods was missing in some investigations (case source: 260/552, 47%; case definition: 310/552, 56%; testing method: 127/552, 23%). Among those with information of case source and case definition provided, the majority of investigations (152/292, 52%) identified RSV cases from inpatients, and ARI or ILI (150/242, 62%) was the most frequently used syndromic

definitions to screen patients for RSV testing, and antigen (325/552, 59%) and nucleic acid detections (323/552, 59%) were the most commonly used laboratory testing methods in more recent publications (Table 1, Supplementary Table 1, Supplementary Figures 2-3). The majority of investigations (373/552, 68%) applied quantitative methods to determine the time of the start, peak and/or end of seasons, and among these studies, over half of the investigations used the threshold-based method (205/373, 55%) (Supplementary Tables 2-3).

174

175 The majority of the investigations were conducted using data collected from locations in the 176 Northern Hemisphere (NH) and indicated one RSV season every year (Figure 2). A small 177 number of investigations (11/552, 2%) reported two RSV peaks identified in one year 178 (Supplementary Table 4) while 18 (3%) investigations indicated unique RSV seasonal 179 patterns repeated every 2 years (Supplementary Table 5). Among study sites reporting one 180 RSV season annually, locations in temperate countries were fairly consistent in the time of 181 the start, peak and end of RSV seasons in either the NH or Southern Hemisphere (SH) 182 (Figure 3). In temperate countries, RSV activities generally started from late autumn or early 183 winter, i.e., October-December in NH, May-June in SH, peaked in winter (December-184 February in NH, and June to July in SH), and ended in late winter or spring (February-May in 185 NH, and July-September in SH). (Figure 3, Supplementary Figure 4). Larger variations were 186 observed in the start, peak and end month of RSV seasons in subtropical and tropical 187 countries at a lower latitude, with high RSV activities observed in July/August-November in 188 tropical locations (Supplementary Figures 5-6). The durations of RSV seasons were relatively 189 shorter in study sites in the temperate region (median: 3.97 months, interquartile range (IQR): 190 3.00-5.00) compared with the estimates from subtropical (4.00, 3.52-6.14) and tropical 191 countries (5.00, 4.00-6.00) (Figure 2, Supplementary Figure 6).

193 The Pearson correlation analysis indicated an overall negative association between the 194 duration of the RSV season (in months) and the latitude both in the NH (p<0.001) and the SH 195 (p=0.002) (Supplementary Table 7), and the statistical significance in the association was 196 only indicated with the estimates derived from quantitative methods (p<0.001). Positive 197 associations were indicated in the correlation analyses between the daily average mean 198 temperature (correlation coefficient: 0.33; 95% CI: 0.22, 0.44) and absolute humidity (0.34; 199 0.22, 0.45) of the study locations and the durations of RSV season estimated by the 200 quantitative methods (p < 0.001) but not for those estimated by the qualitative methods 201 (Supplementary Table 7). Durations of RSV seasons appeared to be longer in tropical 202 /subtropical regions than the estimates from temperate regions, and the estimated RSV 203 seasons were longer from the threshold-based methods, but shorter from the coverage-based 204 method (Table 2, Supplementary Table 8).

205

206 In the main analysis with the linear regression model, we identified that climatic zone 207 appeared to be independently associated with the estimated duration of RSV seasons, and analytic method used in estimating RSV seasons, annual daily average mean absolute 208 humidity at the study location could also explain some variations (Adjusted $R^2=0.33$ for 209 210 estimates from quantitative approaches, 0.25 for all estimates) in the estimated durations of 211 RSV seasons (Table 2, Supplementary Table 8). Considering the close intercorrelations 212 between climatic zone, latitude and temperature, we included the climatic zone (Table 2, 213 Supplementary Table 8), latitude (Supplementary Tables 9-10) and daily average mean 214 temperature (Supplementary Tables 11-12) of study locations into different linear regression 215 models separately. The duration of RSV season would decrease by 0.041 (95% CI: 0.017, 216 0.064) months with every increase of 1 degree in latitude, and increase by 0.058 (95%CI: 217 0.0077, 0.11) months with every increase of 1 degree in daily average mean temperature.

Durations of RSV seasons estimated for the subtropical and tropical locations were on average 1.06 (95% CI: 0.45, 1.66) and 1.65 (95% CI: 0.77, 2.54) months longer than for the study sites in the temperate region. Compared to the coverage-based methods, the thresholdbased methods tended to produce longer estimates of the duration of RSV season by 1.43 (95% CI: 0.96, 1.90) months. Overall, the duration of RSV season prolonged by 0.013 (95% CI: -0.0048, 0.030) months with every 1 g/m³ increase in absolute humidity at the study location (Table 2).

225

226 **DISCUSSION**

227 RSV seasonal patterns have been studied widely in particular since the last decade, with most 228 of the data reported from temperate countries in the Northern Hemisphere. Our review 229 indicated that largely similar seasonal patterns of RSV were observed in locations from the 230 same climatic region either in the NH or the SH. In temperate regions, RSV activities 231 primarily showed regular annual patterns starting in winter seasons, and the estimated 232 durations of RSV season were relatively shorter than the reported from tropical and 233 subtropical regions where prolonged RSV circulations were often more than half a year with 234 greatly varied times of season start and/or peak.

235

Human infections of RSV are likely driven by two major antigenic groups, A and B ²⁴ between which cross-immunity has been suggested ^{25,26}. However, RSV typing is often not included in most of the established surveillance systems ²⁷. The increasing susceptibility in infants due to the loss of protection from waning maternal antibodies leads to a higher risk of infection particularly in young children with high-risk conditions ^{1,28,29}, potentially driving the transmission of RSV in the population ³⁰ although the virus can infect people at any age including older adults ^{31,32}. RSV shows comparable environmental survivability and

medRxiv preprint doi: https://doi.org/10.1101/2023.06.12.23291266; this version posted June 12, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

transmissibility to influenza viruses with a similar estimate of the basic reproduction number (R_0) and household second attack rate ³³. Increasing RSV activities were commonly reported in cold seasons starting from late autumn through to early spring in temperate regions, and in rainy seasons in tropical/subtropical areas, and the associations between RSV activities and environmental factors including temperature, relative/absolute humidity, rainfall were inconsistently reported from studies conducted in tropical areas ³⁴⁻³⁶.

249

250 RSV seasonality characterised in different studies appeared to be associated with the approaches used in data collection and analysis ¹⁹. Previous research demonstrated that the 251 252 timing of RSV seasons determined with laboratory surveillance data might be different from 253 the results based on hospitalized patient data although the two estimates were highly 254 correlated ³⁷. The improvement of laboratory testing methods could also affect the estimates of RSV seasons ^{38,39}. Our review showed that estimates of the timing of RSV seasons were 255 256 correlated with the analytic approaches used in the studies, with shorter durations of RSV 257 seasons estimated from "coverage-based method" (defined as the shortest time period when 258 the majority of confirmed (severe) RSV infections occurred) than the estimates from the 259 threshold-based methods which although were highly dependent on the often arbitrarily 260 selected threshold of varied measures for RSV activities, such as proportion of virus detections or patients presenting ILI/ARI symptoms ⁴⁰. Therefore, prudent comparison and 261 262 interpretation of RSV seasons estimated from different studies or with different approaches is 263 necessary.

264

RSV surveillance is often established based on the existing routine surveillance on influenza, more commonly seen in developed economies including the US ⁴¹, Canada ⁴² and some European countries ⁴³. The WHO initiated a pilot RSV surveillance scheme by leveraging the

268 current Global Influenza Surveillance and Response System covering over 100 countries to 269 explore possible surveillance strategies including case definitions, laboratory methods and 270 target population, etc. ⁴⁴. Current RSV surveillance largely applied similar syndromic case 271 definitions as those used for influenza surveillance, i.e., sampling patients showing influenza-272 like-illness and testing for the virus, while the validity of using such case definitions for RSV 273 surveillance has been questioned ⁴⁵. In some countries/areas RSV surveillance was not 274 conducted throughout a year but only during restricted period(s) following the influenza 275 surveillance protocol given the regular annual influenza seasons in those locations ^{17,46}. 276 However, this might lead to an underreporting of RSV infections during the non-surveillance 277 periods ⁴⁷.

278

279 During the COVID-19 pandemic, circulation of respiratory viruses including RSV changed 280 considerably worldwide largely due to implementation of non-pharmaceutical interventions and changes in human behaviours in response to the pandemic ^{48,49}. RSV remained at a low 281 282 level in many countries in 2020 when public health and social measure were widely adopted 283 globally to contain the spread of SARS-CoV-2, but caused surges of infections with a large 284 number of severe cases admitted into hospital in some countries when some interventions were relaxed from 2021 onwards ^{50,51}, including the US during 2021-2023 ⁵², some 285 geographically separated locations in Australia in 2020-21⁵³ and the UK in 2021-22⁵⁴. The 286 287 inter-seasonal viral activities were perhaps related to the increased susceptibility in the 288 population due to the lack of exposure to RSV during the previous year in response to COVID-19⁵⁵. 289

290

291 Monoclonal antibodies approved for prophylactic therapy provide immediate protection of 292 high-risk individuals particularly young children against RSV-associated severe infections ^{7,13}.

293 Five monthly injections of palivizumab and a single dose of nirsevimab can substantially 294 reduce the risk of hospitalizations due to RSV in individuals receiving the therapy throughout 295 RSV seasons especially in temperate regions where RSV seasons would normally not be 296 longer than 5 months. The duration of protection provided by RSV vaccines has not been 297 fully determined although promising efficacy for short-term prevention from infections was 298 demonstrated in clinical trials ⁵⁶⁻⁵⁸. The effectiveness of the abovementioned pharmaceutical 299 interventions for high-risk population is determined by the duration of protection of the 300 monoclonal antibodies and the vaccines, the timing of administration and RSV activities in 301 specific locations. Ideally these preventive measures should be administered before an RSV 302 season starts, and the protection can maintain throughout the season, likely during November 303 - April, and May - October in temperate regions of the NH and the SH, respectively. 304 However great challenges in implementing these efficacious interventions would be seen in 305 locations where there were irregular seasons particularly with prolonged viral circulations ⁵⁹⁻ ⁶¹. Based on the reported seasonal patterns in locations from northern temperate regions in 306 307 this review, the Studies incorporating epidemiologic analysis on RSV seasonality into the 308 effectiveness and cost-effectiveness of these RSV preventive strategies are urgently needed ⁶². 309

310 There are several limitations in this study. First, data of RSV seasonality that were published 311 and included in the review were skewed to high-income countries with well-established RSV 312 surveillance systems. These countries are largely in temperate regions where RSV circulation 313 might be different from the underrepresented middle- and low-income countries due to varied population structure, contact patterns and geoclimatic features ⁶³. Second, RSV antigenic 314 315 information could not be incorporated into the current analysis of seasonality due to the lack 316 of data. Expanding RSV surveillance by collecting antigenic and genetic data is urgently 317 needed to improve our understanding of the transmission dynamics of RSV locally and

318 globally ⁶⁴. Third, except for the analytic method, we could not examine potential 319 associations between RSV seasonality and other study characteristics such as case sources, 320 case definitions, and laboratory methods due to the lack of information and non-standardized 321 laboratory protocols used for RSV surveillance, or explore the association between RSV 322 seasonality and population structure particularly birth rate given the lack of data although a high disease burden of RSV identified in young children⁶⁵⁻⁶⁷ implied a possible driving force 323 324 from the young population on RSV activities. Lastly, the reported data of seasonality in this 325 review did not allow us to investigate the RSV-associated disease burden occurred during the 326 characterised RSV seasons which is a critical metric for evaluation of the health impact 327 related to RSV circulation, particularly when there were large uncertainties in the start and 328 the end of RSV seasons in a specific location and the infection risk is less likely to be 329 homogeneous in a population over the season.

330

331 CONCLUSIONS

This study provided a global overview of RSV seasonality before the COVID-19 pandemic. The seasonal patterns illustrated in this review may inform optimal use of preventive and therapeutic interventions against RSV infection particularly in temperate regions of the NH and SH. Considerable variations in methods used by different studies highlighted the importance of developing and applying standardized approaches in RSV surveillance and data reporting. Further research is needed to understand the underlying mechanisms driving RSV seasonal patterns locally and globally.

340

341 ACKNOWLEDGEMENTS

The authors thank Prof. Julian W Tang, and Dr. Eeva Broberg for kindly sharing the data of
RSV seasonality from their publications. The authors also thank Stella SW Lai for technical
assistance.

345

346 FUNDING

347 This project was supported by the Health and Medical Research Fund (project no. 19200861)

348 from Food Bureau of Hong Kong SAR Government, and the AIR@InnoHK administered by

349 the Innovation and Technology Commission of Hong Kong SAR Government. The funding

bodies had no role in study design, data collection and analysis, preparation of the manuscript,

351 or the decision to publish.

352

353 AUTHOR CONTRIBUTIONS

All authors meet the International Committee of Medical Journal Editors criteria for authorship. SS, PW, BY, DZ conceived and designed the study; SS, WZ, HG, PH collected and extracted data; SS, PW conducted the data analysis and wrote the first draft of the manuscript. All authors contributed to the interpretation of the results and revision of the manuscript, and have approved the final version of the manuscript.

359

360 DECLATATION OF INTERESTS

361 JN was previously employed by and owns shares in Sanofi. The authors report no other

362 potential conflicts of interest.

Li Y, Wang X, Blau DM, et al. Global, regional, and national disease burden estimates of

acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in

364 **REFERENCES**

1.

365

366

367

- 368 2019: a systematic analysis. Lancet 2022; 399(10340): 2047-64. 369 2. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due 370 to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010; 371 **375**(9725): 1545-55. 372 3. Shi T, McLean K, Campbell H, Nair H. Aetiological role of common respiratory viruses in 373 acute lower respiratory infections in children under five years: A systematic review and meta-analysis. 374 J Glob Health 2015; 5(1): 122-31. 375 4. Falsey AR, McElhaney JE, Beran J, et al. Respiratory syncytial virus and other respiratory 376 viral infections in older adults with moderate to severe influenza-like illness. J Infect Dis 2014; 377 **209**(12): 1873-81. 378 5. Falsey AR, Walsh EE. Respiratory syncytial virus infection in elderly adults. Drugs Aging 379 2005; 22(7): 577-87. 380 6. Troeger C, Forouzanfar M, Rao PC, et al. Estimates of the global, regional, and national 381 morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a 382 systematic analysis for the Global Burden of Disease Study 2015. Lancet Infect Dis 2017; 17(11): 383 1133-61. 384 7. Brady MT, Byington CL, Davies HD, et al. Updated Guidance for Palivizumab Prophylaxis 385 Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial 386 Virus Infection. *Pediatrics* 2014; **134**(2): E620-E38. 387 8. Reeves RM, van Wijhe M, Lehtonen T, et al. A Systematic Review of European Clinical 388 Practice Guidelines for Respiratory Syncytial Virus Prophylaxis. J Infect Dis 2022; 226(Suppl 1): 389 S110-S6.
- 390 9. Hammitt LL, Dagan R, Yuan Y, et al. Nirsevimab for Prevention of RSV in Healthy Late391 Preterm and Term Infants. *N Engl J Med* 2022; **386**(9): 837-46.

- 392 10. Simoes EAF, Madhi SA, Muller WJ, et al. Efficacy of nirsevimab against respiratory
- 393 syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic
- 394 extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of
- randomised controlled trials. *Lancet Child Adolesc Health* 2023; **7**(3): 180-9.
- 396 11. Garegnani L, Styrmisdottir L, Roson Rodriguez P, Escobar Liquitay CM, Esteban I, Franco
- 397 JV. Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children.
- 398 *Cochrane Database Syst Rev* 2021; **11**(11): CD013757.
- 399 12. Null D, Bimle C, Weisman L, et al. Palivizumab, a humanized respiratory syncytial virus
- 400 monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk
- 401 infants. *Pediatrics* 1998; **102**(3): 531-7.
- 402 13. Keam SJ. Nirsevimab: First Approval. Drugs 2023; 83(2): 181-7.
- 403 14. Mazur NI, Terstappen J, Baral R, et al. Respiratory syncytial virus prevention within reach:
- 404 the vaccine and monoclonal antibody landscape. *Lancet Infect Dis* 2023; **23**(1): E2-E21.
- 405 15. Valero MV. Green light from US regulatory agency for GSK's jab caps off a decades-long
 406 quest. 2023. <u>https://www.nature.com/articles/d41586-023-01529-5</u> (accessed May 6 2023).
- 407 16. Li Y, Reeves RM, Wang X, et al. Global patterns in monthly activity of influenza virus,
- 408 respiratory syncytial virus, parainfluenza virus, and metapneumovirus: a systematic analysis. Lancet
- 409 *Glob Health* 2019; **7**(8): e1031-e45.
- 410 17. Obando-Pacheco P, Justicia-Grande AJ, Rivero-Calle I, et al. Respiratory Syncytial Virus
- 411 Seasonality: A Global Overview. *J Infect Dis* 2018; **217**(9): 1356-64.
- Broberg EK, Waris M, Johansen K, Snacken R, Penttinen P, European Influenza Surveillance
 N. Seasonality and geographical spread of respiratory syncytial virus epidemics in 15 European
 countries, 2010 to 2016. *Euro Surveill* 2018; 23(5).
- 415 19. Staadegaard L, Caini S, Wangchuk S, et al. Defining the seasonality of respiratory syncytial
- 416 virus around the world: National and subnational surveillance data from 12 countries. *Influenza Other*
- 417 *Respir Viruses* 2021; **15**(6): 732-41.
- 418 20. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and 419 meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015; **4**(1): 1.

- 420 21. Geocoding API. <u>https://developers.google.com/maps/documentation/geocoding</u>.
- 421 22. GSODR: Global Surface Summary of the Day ('GSOD') Weather Data Client. <u>https://cran.r-</u>
- 422 project.org/web/packages/GSODR/index.html.
- 423 23. Khor CS, Sam IC, Hooi PS, Quek KF, Chan YF. Epidemiology and seasonality of respiratory
- 424 viral infections in hospitalized children in Kuala Lumpur, Malaysia: a retrospective study of 27 years.
- 425 *Bmc Pediatr* 2012; **12**.
- 426 24. Sullender WM. Respiratory syncytial virus genetic and antigenic diversity. *Clin Microbiol*
- 427 *Rev* 2000; **13**(1): 1-15, table of contents.
- 428 25. Bhattacharyya S, Gesteland PH, Korgenski K, Bjornstad ON, Adler FR. Cross-immunity
- 429 between strains explains the dynamical pattern of paramyxoviruses. P Natl Acad Sci USA 2015;
- **430 112**(43): 13396-400.
- 431 26. White LJ, Waris M, Cane PA, Nokes DJ, Medley GF. The transmission dynamics of groups
- 432 A and B human respiratory syncytial virus (hRSV) in England & Wales and Finland: seasonality and
- 433 cross-protection. *Epidemiol Infect* 2005; **133**(2): 279-89.
- 434 27. Chadha M, Hirve S, Bancej C, et al. Human respiratory syncytial virus and influenza
- 435 seasonality patterns-Early findings from the WHO global respiratory syncytial virus surveillance.
- 436 Influenza Other Resp 2020; **14**(6): 638-46.
- 437 28. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection
 438 in young children. *N Engl J Med* 2009; **360**(6): 588-98.
- 439 29. Meissner HC. Selected populations at increased risk from respiratory syncytial virus infection.
 440 *Pediatr Infect Dis J* 2003; **22**(2): S40-S5.
- 441 30. Hogan AB, Glass K, Moore HC, Anderssen RS. Exploring the dynamics of respiratory
- 442 syncytial virus (RSV) transmission in children. *Theor Popul Biol* 2016; **110**: 78-85.
- 443 31. Savic M, Penders Y, Shi T, Branche A, Pircon JY. Respiratory syncytial virus disease burden
- 444 in adults aged 60 years and older in high-income countries: A systematic literature review and meta-
- 445 analysis. Influenza Other Resp 2023; 17(1).

- 446 32. Shi T, Denouel A, Tietjen AK, et al. Global Disease Burden Estimates of Respiratory
- 447 Syncytial Virus-Associated Acute Respiratory Infection in Older Adults in 2015: A Systematic
- 448 Review and Meta-Analysis. J Infect Dis 2020; 222: S577-S83.
- 449 33. Leung NHL. Transmissibility and transmission of respiratory viruses. *Nat Rev Microbiol*450 2021; **19**(8): 528-45.
- 451 34. Moriyama M, Hugentobler WJ, Iwasaki A. Seasonality of Respiratory Viral Infections. Annu
- 452 *Rev Virol* 2020; **7**: 83-101.
- 453 35. Paynter S. Humidity and respiratory virus transmission in tropical and temperate settings.
- 454 *Epidemiol Infect* 2015; **143**(6): 1110-8.
- 455 36. Tang JLW, Loh TP. Correlations between climate factors and incidence-a contributor to RSV
- 456 seasonality. *Rev Med Virol* 2014; **24**(1): 15-34.
- 457 37. Hampp C, Asal N, Lipowski E, et al. Validity of Laboratory-based Surveillance for Detection
- 458 of Respiratory Syncytial Virus Seasons. *Am J Epidemiol* 2013; **177**(8): 841-51.
- 459 38. Ambrose CS, Steed LL, Brandon M, Frye K, Olajide IR, Thomson G. National and regional
- 460 modeling of distinct RSV seasonality thresholds for antigen and PCR testing in the United States. J
- 461 *Clin Virol* 2019; **120**: 68-77.
- 462 39. Midgley CM, Haynes AK, Baumgardner JL, et al. Determining the Seasonality of Respiratory
- 463 Syncytial Virus in the United States: The Impact of Increased Molecular Testing. J Infect Dis 2017;
- **464 216**(3): 345-55.
- 465 40. Rose EB, Wheatley A, Langley G, Gerber S, Haynes A. Respiratory Syncytial Virus
- 466 Seasonality United States, 2014-2017. *Mmwr-Morbid Mortal W* 2018; **67**(2): 71-6.
- 467 41. National Respiratory and Enteric Virus Surveillance System.
 468 https://www.cdc.gov/surveillance/nrevss/index.html.
- 469 42. Flu (influenza): FluWatch surveillance Canada.ca. <u>https://www.canada.ca/en/public-</u>
 470 health/services/diseases/flu-influenza/influenza-surveillance.html.
- 471 43. Surveillance Atlas of Infectious Diseases. <u>https://atlas.ecdc.europa.eu/public/index.aspx</u>.

- 472 44. Broor S, Campbell H, Hirve S, et al. Leveraging the Global Influenza Surveillance and
- 473 Response System for global respiratory syncytial virus surveillance-opportunities and challenges.
- 474 Influenza Other Resp 2020; 14(6): 622-9.
- 475 45. Hirve S, Crawford N, Palekar R, Zhang WQ, Grp WRS. Clinical characteristics, predictors,
- 476 and performance of case definition-Interim results from the WHO global respiratory syncytial virus
- 477 surveillance pilot. *Influenza Other Resp* 2020; **14**(6): 647-57.
- 478 46. Teirlinck AC, Broberg EK, Berg AS, et al. Recommendations for respiratory syncytial virus
- 479 surveillance at the national level. *Eur Respir J* 2021; **58**(3).
- 480 47. Mollers M, Barnadas C, Broberg EK, et al. Current practices for respiratory syncytial virus
- 481 surveillance across the EU/EEA Member States, 2017. *Euro Surveill* 2019; 24(40).
- 482 48. Baker RE, Park SW, Yang W, Vecchi GA, Metcalf CJE, Grenfell BT. The impact of COVID-
- 483 19 nonpharmaceutical interventions on the future dynamics of endemic infections. Proc Natl Acad Sci
- 484 USA 2020; **117**(48): 30547-53.
- 485 49. Oh DY, Buda S, Biere B, et al. Trends in respiratory virus circulation following COVID-19-
- 486 targeted nonpharmaceutical interventions in Germany, January September 2020: Analysis of

487 national surveillance data. *Lancet Reg Health Eur* 2021; **6**: 100112.

- 488 50. Bozzola E, Barni S, Villani A. Respiratory Syncytial Virus Pediatric Hospitalization in the
 489 COVID-19 Era. *Int J Environ Res Public Health* 2022; 19(23).
- 490 51. Fairbank R. RSV wave hammers hospitals but vaccines and treatments are coming. *Nature*491 2022.
- 492 52. Lindsey Wang PBD, Nathan A Berger, David C Kaelber, Nora D Volkow, Rong Xu.
 493 Disruption in seasonality, patient characteristics and disparities of respiratory syncytial virus infection
 494 among young children in the US during and before the COVID-19 pandemic: 2010-2022. medRxiv;
 495 2022.
- 496 53. Eden JS, Sikazwe C, Xie RP, et al. Off-season RSV epidemics in Australia after easing of
 497 COVID-19 restrictions. *Nat Commun* 2022; 13(1).
- 498 54. Bardsley M, Morbey RA, Hughes HE, et al. Epidemiology of respiratory syncytial virus in
 499 children younger than 5 years in England during the COVID-19 pandemic, measured by laboratory,

- 500 clinical, and syndromic surveillance: a retrospective observational study. Lancet Infect Dis 2023;
- **501 23**(1): 56-66.
- 502 55. Garg I, Shekhar R, Sheikh A, Pal S. Impact of COVID-19 on the Changing Patterns of
- 503 Respiratory Syncytial Virus Infections. *Infect Dis Rep* 2022; **14**(4): 558-68.
- 504 56. Falsey AR, Williams K, Gymnopoulou E, et al. Efficacy and Safety of an Ad26.RSV.preF-
- 505 RSV preF Protein Vaccine in Older Adults. N Engl J Med 2023; 388(7): 609-20.
- 506 57. Kampmann B, Madhi SA, Munjal I, et al. Bivalent Prefusion F Vaccine in Pregnancy to
- 507 Prevent RSV Illness in Infants. *N Engl J Med* 2023; **388**(16): 1451-64.
- 508 58. Walsh EE, Perez Marc G, Zareba AM, et al. Efficacy and Safety of a Bivalent RSV Prefusion
- 509 F Vaccine in Older Adults. *N Engl J Med* 2023; **388**(16): 1465-77.
- 510 59. Bauman J, Eggleston M, Oquist N, Malinoski F. Respiratory syncytial virus: Seasonal data
- 511 for regions of Florida and implications for palivizumab. *South Med J* 2007; **100**(7): 669-76.
- 512 60. Hsu CH, Lin CY, Chi H, et al. Prolonged Seasonality of Respiratory Syncytial Virus Infection
- 513 among Preterm Infants in a Subtropical Climate. *Plos One* 2014; 9(10).
- 514 61. Janet S, Broad J, Snape MD. Respiratory syncytial virus seasonality and its implications on

515 prevention strategies. *Hum Vacc Immunother* 2018; **14**(1): 234-44.

- 516 62. Getaneh AM, Li X, Mao Z, et al. Cost-effectiveness of monoclonal antibody and maternal
- 517 immunization against respiratory syncytial virus (RSV) in infants: Evaluation for six European
- 518 countries. *Vaccine* 2023; **41**(9): 1623-31.
- 519 63. Tang JW, Lam TT, Zaraket H, et al. Global epidemiology of non-influenza RNA respiratory
- 520 viruses: data gaps and a growing need for surveillance. *Lancet Infect Dis* 2017; **17**(10): E320-E6.
- 521 64. Staadegaard L, Meijer A, Rodrigues AP, et al. Temporal Variations in Respiratory Syncytial
- 522 Virus Epidemics, by Virus Subtype, 4 Countries. *Emerg Infect Dis* 2021; **27**(5): 1537-40.
- 523 65. Glatman-Freedman A, Kaufman Z, Applbaum Y, et al. Respiratory Syncytial Virus
- 524 hospitalization burden: a nation-wide population-based analysis, 2000-2017. J Infect 2020; 81(2):
- 525 297-303.

- 526 66. Johannesen CK, van Wijhe M, Tong S, et al. Age-Specific Estimates of Respiratory Syncytial
- 527 Virus-Associated Hospitalizations in 6 European Countries: A Time Series Analysis. J Infect Dis
- 528 2022; **226**(Suppl 1): S29-S37.
- 529 67. Tong S, Amand C, Kieffer A, Kyaw MH. Incidence of respiratory syncytial virus related
- 530 health care utilization in the United States. *J Glob Health* 2020; **10**(2): 020422.

532 Table 1. Characteristics of publications and investigations included in the systematic

533 review.

Characteristics	No. of Publications (N=209) ^a n (%)	No. of Investigations (N = 552) n (%)
Climatic zone		
Temperate (>35°)	123 (58.9)	335 (60.7)
Subtropical (23.5° - 35°)	65 (31-1)	134 (24.3)
Tropical (equator - 23.5°)	49 (23.4)	83 (15.0)
Continent		
Asia	64 (30.6)	140 (25.4)
Europe	68 (32.5)	155 (28.1)
North America	38 (18·2)	164 (29.7)
South America	14 (6.7)	49 (8.9)
Africa	12 (5.7)	24 (4.3)
Oceania	5 (2.4)	19 (3.4)
Others ^b	8 (3.8)	1 (0.2)
Study period $^{\circ}$		
Before Palivizumab approved	88 (42.1)	147 (26.6)
After Palivizumab approved	75 (35.9)	320 (58.0)
Others ^d	46 (22.0)	85 (15.4)
Length of study period		
3-6 years	127 (60.8)	342 (62.0)
7-10 years	53 (25.4)	123 (22.3)
> 10 years	37 (17.7)	87 (15.8)
Type of RSV data		
Weekly data	57 (27.3)	294 (53.3)
Monthly data	155 (74-2)	258 (46.7)
Analytic method		
Qualitative	146 (69.9)	179 (32.4)
Quantitative	66 (31.6)	373 (67.6)

Threshold-based	54 (25.9)	205 (37.1)
Coverage-based	8 (3.8)	142 (25.7)
Model-based	6 (2.9)	26 (4.7)
RSV case source		•
Inpatient	94 (45.0)	152 (27.5)
Outpatient	14 (6.7)	25 (4.5)
Both	53 (25.4)	115 (20.8)
Unknown	48 (23.0)	260 (47.1)
RSV case definition ^e		
ARI or ILI	82 (39-2)	150 (27.2)
SARI	23 (11.0)	45 (8.2)
ALRI	48 (23.0)	59 (10.7)
Clinical judgement	9 (4.3)	30 (5.4)
Unknown	70 (33.5)	310 (56-2)
Testing method ^f		
Virus detection	45 (21.5)	168 (30.4)
Antigen detection	107 (51.2)	303 (54.9)
Antibody detection	8 (3.8)	42 (7.6)
Nucleic acid detection	110 (52.6)	323 (58.5)
Unknown	33 (15.8)	127 (23.0)

534 Note: ARI, acute respiratory infection; ILI, influenza-like illness; SARI, severe acute respiratory infection;

535 ALRI, acute lower respiratory infection

^aAn investigation was identified as an analysis with a specified method on the reported RSV data for the seasonality of RSV activities. Analyses on the same data with different analytic methods were recognized as different investigations. A publication might include several investigations describing the seasonality of RSV activities by analysing different sets of data, or applying different analytic methods, etc. Therefore, the sum of investigations might be greater than the total number of publications.

^bRefers to the publications/investigations with study sites involving more than one continent.

542 ^c For different locations, the time for palivizumab to be licensed for prophylactic use are different. For the 543 countries where palivzumab has not been licensed, such as China, all the publications/investigations of this 544 country would be recognized as "before palivzumab approved".

545 ^d Refers to the publications/investigations in which the study period contains the periods both before and after 546 the year when Palivizumab was approved in the study locations.

⁶ A publication/investigation on RSV seasonality might be based on multiple sources of cases, e.g., ARI, ILI and
SARI perhaps were used together or in different combinations to identify patients for RSV testing. Some
investigations/studies might be counted multiple times, and the sum of the proportions of
publications/investigations from different case definition categories may exceed 100%.

^f A publication/investigation on RSV seasonality might adopt multiple testing methods for RSV detection. Some investigations/studies might be counted multiple times, and the sum of the proportions of publications/investigations from different testing method categories may exceed 100%.

554 Table 2. Associations identified in the linear regression analysis between durations of

- **RSV** seasons estimated from quantitative approaches and characteristics of the studies.

Variable	Change in duration of RSV season (months)	95% confidence interval	p-value		
Climatic zone					
Temperate region (<-35° or >35°)	0	Referent			
Subtropical region (-35°23·5° or 23·5°- 35°)	1.06	0.45, 1.66	<0.001		
Tropical region $(-23 \cdot 5^{\circ} - 23 \cdot 5^{\circ})$	1.65	0.77, 2.54	<0.001		
Analysis method					
Coverage-based method	0	Referent			
Threshold-based method	1.43	0.96, 1.90	<0.001		
Model-based method	1.98	-0.99, 4.95	0.19		
Meteorological factor					
Daily average mean absolute humidity	0.013	-0.0049, 0.030	0.15		

558 FIGURE LEGENDS

559 Figure 1. Flowchart of study identification and selection for the systematic review.

Figure 2. Geographic distribution of study locations and the reported RSV seasonal
patterns from all included investigations using either quantitative or qualitative
approaches.

563 Figure 3. The timing of one-peak RSV seasons reported in investigations using either 564 quantitative or qualitative approaches against the latitude of the study site located in 565 the Northern Hemisphere (NH, centred at the north pole) in panels A, C and E, and 566 Southern Hemisphere (SH, centred at the south pole) in panels B, D and F. The start (A), 567 peak (C) and end (E) of RSV seasons in NH. The start (B), peak (D) and end (F) of RSV 568 seasons in SH. The centre of the radius circles represents the north pole or the south pole 569 (latitude = 90°) and the external border represents the equator (latitude = 0°). The circles 570 were divided by the dashed radiuses into 12 sections to represent 12 months of a year. Two 571 radius circles between the north/south pole and the external border indicating the latitudes at 572 23.5° and 35° are used to define the temperate region ($35^{\circ}-90^{\circ}$), subtropical region ($23.5^{\circ}-35^{\circ}$) 573 and tropical region (equator-23.5°).















F.

